Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Lorlatinib in ROS1-Rearranged Advanced NSCLC
KCT0003338Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started May 2019; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003338.